
CHMP rejects rare bone disease treatment in EU
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorisation for Ipsen’s investigational palovarotene as a treatment for fibrodysplasia ossificans progressiva (FOP). The company says it will be requesting a re-examination of the CHMP opinion, based on scientific… Read More


